Beranda › Kanker Paru › Texas › San Antonio
Uji klinis Kanker Paru di San Antonio, TX
26 studi untuk Kanker Paru mencari peserta di lokasi sekitar San Antonio (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Audie L Murphy VA Hospital, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- University of Texas San Antonio (UTSA), San Antonio
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Menerima pesertaFase 2/3
- Local Institution - 0173, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Menerima pesertaFase 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Menerima pesertaFase 1/2
- START San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- START - San Antonio, San Antonio
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, San Antonio
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Menerima pesertaFase 1
- START San Antonio, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- START - San Antonio, San Antonio
IDOV-Immune for Advanced Solid Tumors
Menerima pesertaFase 1
- South Texas Accelerated Research Therapeutics, San Antonio
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Menerima peserta
- Audie Murphy VA Medical Center, San Antonio
- Brooke Army Medical Center, San Antonio
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Menerima pesertaFase 1/2
- Mays Cancer Center / University of Texas, San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Menerima pesertaFase 1
- NEXT Oncology, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- START, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Menerima pesertaFase 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Next Oncology, San Antonio
A Study of ZW251 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- START San Antonio, San Antonio
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Menerima pesertaStudi observasional
- UT Health San Antonio, M.D. Anderson Cancer Center, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Menerima pesertaFase 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Menerima pesertaFase 1/2
- Next Oncology, San Antonio, San Antonio
Collection of Sputum and Labeling for Lung Cancer
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital, San Antonio
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di San Antonio
- Kanker Paru Non-Sel Kecil59 studi
- Kanker Kolorektal46 studi
- Kanker Payudara46 studi
- Kanker Metastatik44 studi
- Kanker (semua jenis)41 studi
- Obesitas40 studi
- Diabetes Tipe 237 studi
- Kelebihan Berat Badan34 studi
- Kanker Ovarium31 studi
- Kanker Pankreas31 studi
- Kanker Prostat28 studi
- Kanker Endometrium27 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.